metadata stringlengths 367 1.57k | data stringlengths 358 5.41k | criteria stringlengths 251 8.32k | __index_level_0__ int64 1 94 |
|---|---|---|---|
{
"NCT_ID" : "NCT02813252",
"Brief_Title" : "Long-Term Follow-up Study for Patients Previously Treated With JCAR015",
"Official_title" : "Long-Term Follow-up Protocol for Subjects Treated With JCAR015",
"Conditions" : ["Acute Lymphoblastic Leukemia"],
"Interventions" : ["Genetic: JCAR015"],
"Location_Countries" : [... | #Study Description
Brief Summary
This study will provide long-term follow-up for patients who have received treatment with JCAR015 in a previous clinical trial. In this study, patients will be followed for up to 15 years after their last dose of JCAR015 for evaluation of delayed adverse events, presence of persisting... | #Eligibility Criteria:
Inclusion criteria:
* Patients who have received at least one dose of JCAR015 in a previous treatment protocol.
* Patients who have provided informed consent for the long-term follow-up study prior to study participation.
Exclusion criteria:
* None. All patients who have previously received JC... | 66 |
{
"NCT_ID" : "NCT05130489",
"Brief_Title" : "CAR T Cell Therapy Related Cardiovascular Outcomes",
"Official_title" : "Chimeric Antigen Receptor (CAR) Cell Therapy Related Cardiovascular Outcomes",
"Conditions" : ["Cardiovascular Diseases", "B-cell Acute Lymphoblastic Leukemia", "B-cell Lymphoma Refractory", "B-cell L... | #Study Description
Brief Summary
This will be a cohort study of all patients receiving Cluster of Differentiation 19 (CD19)-specific CAR T cell therapy for relapsed/refractory B cell haematological malignancies. Patients will receive cardiac assessment and have serum cardiac biomarkers, ECG, transthoracic echocardiog... | #Eligibility Criteria:
Inclusion Criteria:
* Patients with capacity, (aged 16 and older)
* Undergoing CAR T cells for treatment for relapsing or refractory haematological malignancies
Exclusion Criteria:
* Patients under 16 years
Sex :
ALL
Ages :
- Minimum Age : 16 Years
- Age Group (Child: birth-17, Adult: 18-64, ... | 15 |
{
"NCT_ID" : "NCT03726515",
"Brief_Title" : "CART-EGFRvIII + Pembrolizumab in GBM",
"Official_title" : "Phase 1 Study of EGFRvIII-Directed CAR T Cells Combined With PD-1 Inhibition in Patients With Newly Diagnosed, MGMT-Unmethylated Glioblastoma",
"Conditions" : ["Glioblastoma"],
"Interventions" : ["Biological: Pemb... | #Study Description
Brief Summary
This is an open-label, phase 1 study to assess the safety and tolerability of EGFRvIII T cells in combination with pembrolizumab (PD-1 Inhibitor) in patients with newly diagnosed, EGFRvIII+, MGMT-unmethylated glioblastoma.
#Intervention
- BIOLOGICAL : CART-EGFRvIII T cells
- autol... | #Eligibility Criteria:
Inclusion Criteria:
* One of the following diagnoses of GBM:
a. Newly diagnosed glioblastoma multiforme that is histologically confirmed by pathology review of surgically resected tissue; OR b. An integrated molecular/pathologic diagnosis of diffuse astrocytic glioma, IDH-wildtype, with mole... | 78 |
{
"NCT_ID" : "NCT04938115",
"Brief_Title" : "Cell Therapy for CD7 Positive Acute Myeloid Leukemia or Mixed Lineage Leukemia",
"Official_title" : "Cell Therapy for CD7 Positive Acute Leukemia or Mixed Lineage Leukemia Except Those Who Are Diagnosed With T-ALL/T-LBL Using CD7-Specific CAR-T Cells",
"Conditions" : ["Leu... | #Study Description
Brief Summary
This is an open, single-arm, clinical study to evaluate efficacy and safety of anti CD7 CAR-T cell in the treatment of CD7 Positive acute leukemia or mixed lineage leukemia except those who are diagnosed with T-ALL/T-LBL
Detailed Description
The CARs consist of an anti-CD7 VHHs, a p... | #Eligibility Criteria:
Inclusion Criteria:
* Diagnosis of refractory or relapsed CD7+ acute myeloid leukemia or mixed lineage leukemia was made according to the NCCN 2019.V2 guideline. Refractory AML is defined as a patient who has failed to achieve complete remission after induction therapy. Relapsed AML is defined a... | 79 |
{
"NCT_ID" : "NCT01865617",
"Brief_Title" : "Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia",
"Official_title" : "Phase I/II Study of Immunotherapy for Advanced CD19+ Chronic Lymphocytic Leukemia, Acute Lym... | #Study Description
Brief Summary
This phase I/II trial studies the side effects and best dose of laboratory treated T cells to see how well they work in treating patients with chronic lymphocytic leukemia, non-Hodgkin lymphoma, or acute lymphoblastic leukemia that have come back or have not responded to treatment. T ... | #Eligibility Criteria:
Inclusion Criteria:
INCLUSIONS FOR SCREENING AND LEUKAPHERESIS
* Patients with CD19 expressing acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL) or non-Hodgkin lymphoma (NHL)
* Ability to understand and provide informed consent
* Not human immunodeficiency virus (HIV) infec... | 30 |
{
"NCT_ID" : "NCT03068416",
"Brief_Title" : "CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy",
"Official_title" : "CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy - a Phase II Trial.",
"Conditions" : ["B-cell Leukemia", "B-Cell Lymphoma"],
"Interventions" : [... | #Study Description
Brief Summary
Treatment of patients with B cell lymphoma or leukemia with two doses of CD19-targeting chimeric antigen receptor (CAR) T cells to evaluate for safety and efficacy.
Detailed Description
Treatment of patients with B cell lymphoma or leukemia with two doses of CD19-targeting chimeric ... | #Eligibility Criteria:
Inclusion Criteria:
* Relapsed or refractory CD19+ B-cell lymphoma or leukemia with no other curative treatment option available.
* Measurable disease.
* All ages
* Performance status ECOG 0 <= age <= 2.
* Fertile females/males must consent to use contraceptives during participation of the trial... | 33 |
{
"NCT_ID" : "NCT02976857",
"Brief_Title" : "A Phase 1 Study Evaluating Safety and Efficacy of C-CAR011 Treatment in DLBCL Subjects",
"Official_title" : "A Phase 1 Single Center, Non-randomized Study Evaluating Safety and Efficacy of Anti-CD19 Chimeric Antigen Receptor T-cell (C-CAR011) Treatment in Subjects With Refr... | #Study Description
Brief Summary
The trial is a single arm, single-center, non-randomized phase I clinical trial which is designed to evaluate the safety and efficacy of C-CAR011 in treatment of refractory DLBCL
Detailed Description
The 3x3 dose escalation design will be adopted in order to determine the maximum to... | #Eligibility Criteria:
Inclusion Criteria:
* Histologically diagnosed as DLBCL according to the NCCN non-Hodgkin's lymphoma Clinical Practice Guidelines (3rd edition 2016)
* Refractory DLBCL
* All subjects must have received adequate prior therapy including anti-CD20 monoclonal antibody (unless tumor is CD20-negative)... | 11 |
{
"NCT_ID" : "NCT03310619",
"Brief_Title" : "A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies",
"Official_title" : "An Exploratory Phase 1/2 Trial To Evaluate The Safety And Efficacy Of JCAR017 Combinations In Subjects With Relapsed/Refractory B-Cell Malignan... | #Study Description
Brief Summary
This is a global, open-label, multi-arm, parallel multi-cohort, multi-center, Phase 1/2 study to determine the safety, tolerability, PK, efficacy and patient-reported quality of life of JCAR017 in combination with various agents. This protocol is intended to evaluate various drug comb... | #Eligibility Criteria:
Inclusion Criteria:
* Subject is >= 18 years at the time of signing the informed consent form ().
* Subject must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted.
* Subject is willing and able to adhere to the study visit schedule and other... | 44 |
{
"NCT_ID" : "NCT04557436",
"Brief_Title" : "TT52CAR19 Therapy for B-cell Acute Lymphoblastic Leukaemia (B-ALL)",
"Official_title" : "Phase 1, Open Label Study of CRISPR-CAR Genome Edited T Cells (PBLTT52CAR19) in Relapsed /Refractory B Cell Acute Lymphoblastic Leukaemia",
"Conditions" : ["B Acute Lymphoblastic Leuke... | #Study Description
Brief Summary
PBLTT52CAR19 modified T cells are allogenic engineered human T cells (defined as TT52CAR19 +TCRαβ-) prepared for the treatment of CD19+ B cell leukaemia. The cells are from healthy adult volunteer donors and are not HLA-matched. They have been transduced to express and anti-CD19 chime... | #Eligibility Criteria:
Inclusion Criteria:
* Patients with relapsed (second or subsequent bone marrow relapse or bone marrow relapse after allo-SCT) or refractory (not achieving an initial complete response (CR) after 2 cycles of standard chemotherapy) CD19-positive B-acute lymphoblastic leukaemia
* Morphologically co... | 49 |
{
"NCT_ID" : "NCT03585517",
"Brief_Title" : "Safety and Efficacy Evaluation of IM23 CAR-T Cells (IM23CAR-T)",
"Official_title" : "Safety and Efficacy Evaluation of IM23 CAR-T Cells On CD123+ AML Patients",
"Conditions" : ["AML"],
"Interventions" : ["Drug: IM23"],
"Location_Countries" : ["China"],
"Study_Design" : ... | #Study Description
Brief Summary
Assessment of the Safety and Feasibility of Administering T Cells Expressing an Anti-CD123 Chimeric Antigen Receptor to Patients With CD123+ AML
Detailed Description
Assessment of the Safety and Feasibility of Administering T Cells Expressing an Anti-CD123 Chimeric Antigen Receptor ... | #Eligibility Criteria:
Inclusion Criteria:
* Patients with CD123+ Refractory or Relapsed AML
* To be aged 3 <= age <= 80
* Expression of CD123 in Blast >=90%
* ECOG score <=2
* Voluntary participation in the clinical trials and sign the informed consent.
Exclusion Criteria:
* Intracranial hypertension or unconscious... | 31 |
{
"NCT_ID" : "NCT04136275",
"Brief_Title" : "CAR-37 T Cells In Hematologic Malignancies",
"Official_title" : "A Phase I Clinical Trial With CAR-37 T Cells for the Treatment of Patients With Relapsed or Refractory CD37+ Hematologic Malignancies",
"Conditions" : ["Hematologic Malignancy", "Leukemia", "Lymphoma", "Lymph... | #Study Description
Brief Summary
This research study is studying Chimeric Antigen Receptor (CAR)-37 T Cells (CAR-37 T Cells) for treating people with relapsed or refractory CD37+ hematologic malignancies and to understand the side effects when treated with CAR-37 T Cells.
- Chimeric Antigen Receptor (CAR)-37 T Cells... | #Eligibility Criteria:
Inclusion Criteria:
Voluntarily sign informed consent form.
Age >=18 years of at the time of signing informed consent
Eastern Cooperative Oncology Group (ECOG) performance status 0 <= age <= 2 Karnofsky >=60%, see Appendix A)
* Diagnosis of relapsed/refractory (R/R) CD37+ hematologic malignan... | 67 |
{
"NCT_ID" : "NCT03980691",
"Brief_Title" : "Effect of Chidamide Combined With CAT-T or TCR-T Cell Therapy on HIV-1 Latent Reservoir",
"Official_title" : "Effect of Chidamide Combined With CAT-T or TCR-T Cell Therapy on HIV-1 Latent Reservoir",
"Conditions" : ["HIV/AIDS"],
"Interventions" : ["Biological: Chidamide w... | #Study Description
Brief Summary
To study the safety and effectiveness of the combination of Chidamide with Chimeric Antigen Receptor(CAR)-T or T cell receptor(TCR)-T cell therapy on HIV patients based on cART.
Detailed Description
Despite the advent of combined antiretroviral therapy (cART), the persistence of vir... | #Eligibility Criteria:
Inclusion Criteria:
* HIV infection confirmed
* Receiving cART more than 12 months.
* HIV viral-load < 50 copies/ml and CD4 cell count more than 350 cells/ul.
* Without serious liver , heart, liver and kidney diseases.
* The subjects know about the study and volunteer to attend the research and ... | 9 |
{
"NCT_ID" : "NCT03792633",
"Brief_Title" : "Study of huCART19 for Very High-Risk (VHR) Subsets of Pediatric B-ALL",
"Official_title" : "Phase 2 Study of Humanized CD19-directed Chimeric Antigen Receptor-modified T Cells (huCART19) for Very High-Risk Subsets of B Cell Acute Lymphoblastic Leukemia (B-ALL)",
"Condition... | #Study Description
Brief Summary
This is a phase 2 study to evaluate humanized CD19 redirected autologous T cells (or huCART19 cells) with CD19 expressing relapsed and refractory B-cell acute lymphoblastic leukemia. This study is targeting pediatric and young adult patients aged 1-29 years with CD19+ B cell malignanc... | #Eligibility Criteria:
Inclusion Criteria:
* Signed informed consent form must be obtained.
* Relapsed or refractory B-cell ALL:
a. Cohort A: Patients with newly diagnosed VHR B-ALL or high-risk relapse of B-ALL who meet one of the following criteria:
i. Newly diagnosed NCI HR B-ALL with induction failure: M3 ... | 91 |
{
"NCT_ID" : "NCT02445248",
"Brief_Title" : "Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients",
"Official_title" : "A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)",
"Conditions" ... | #Study Description
Brief Summary
This is a multi-center, phase II study to determine the efficacy and safety of CTL019 in adult patients with relapsed or refractory DLBCL.
Detailed Description
This was a single arm, open-label, multi-center, Phase II study conducted to determine the efficacy and safety of tisagenle... | #Eligibility Criteria:
Inclusion Criteria:
* Written informed consent must be obtained prior to any screening procedures
* Histologically confirmed DLBCL at last relapse(by central pathology review before enrolment.
.- Relapsed or refractory disease after >=2 lines of chemotherapy including rituximab and anthracycl... | 5 |
{
"NCT_ID" : "NCT04853277",
"Brief_Title" : "Patient Reported Outcomes and Patient Education in Cellular Therapy Patients",
"Official_title" : "Effect of Patient Education Regarding Emotional Stressors on Patient Reported Outcomes in Patients Undergoing Cellular Therapy (HSCT or CAR-T)",
"Conditions" : ["Stem Cell Tr... | #Study Description
Brief Summary
The purpose of this research is to provide an educational visit addressing common emotional stressors involved in the transplant/CAR-T process, and determine if this added education improves levels of anxiety, depression, and fatigue after transplant/CART in comparison to people who d... | #Eligibility Criteria:
Inclusion Criteria:
* Any patient with an underlying hematologic disease planning to undergo an autologous or allogeneic hematopoietic stem cell transplant (HSCT) or chimeric antigen receptor T-cell (CAR-T) therapy at Dartmouth-Hitchcock Medical Center is eligible.
* The patient must be approved... | 90 |
{
"NCT_ID" : "NCT02765243",
"Brief_Title" : "Anti-GD2 4th Generation CART Cells Targeting Refractory and/or Recurrent Neuroblastoma",
"Official_title" : "Anti-GD2 4th Generation Chimeric Antigen Receptor-modified T Cells (4SCAR-GD2) Targeting Refractory and/or Recurrent Neuroblastoma",
"Conditions" : ["Neuroblastoma"... | #Study Description
Brief Summary
Patients with refractory and/or recurrent neuroblastoma have poor prognosis despite complex multimodel therapy and therefore, novel approaches are urgently needed. The investigators are attempt to treat this disease using T cells genetically modified with a 4th generation lentiviral c... | #Eligibility Criteria:
INCLUSION CRITERIA:
* Patients with neuroblastoma have received standard first-line therapy and been judged to be non-resectable, metastatic, progressive/persistent or recurrent.
* The GD2 antigen status of the neuroblastoma will be determined for eligibility. Positive expression is defined by G... | 70 |
{
"NCT_ID" : "NCT05349201",
"Brief_Title" : "CAR T Cells Real World Evidence Study Based on the French Hospital Claims Data Source (PMSI)",
"Official_title" : "CAR-T Cells - Real Life Study Of Care Pathway And Total Cost Of Care For Patients Under Car T-Cell Treatment Based On The PMSI French Database",
"Conditions" ... | #Study Description
Brief Summary
This was a Retrospective cohort study based on the PMSI data source
Detailed Description
A retrospective database analysis was performed using the French national hospital claims database (Medicalized Information System Program - PMSI, 2015-2019), which includes discharge summaries ... | #Eligibility Criteria:
Inclusion Criteria:
* Patients treated with CAR-T cells from 2017 to 2019 and informed as such in the PMSI And
* Patients diagnosed with ALL or DLBCL when administering CAR-T cells and
* up to 25 years for patients with ALL
Exclusion Criteria:
* All patients treated outside the two types of in... | 35 |
{
"NCT_ID" : "NCT04812691",
"Brief_Title" : "CD19-targeted CAR T Cells （JWCAR029） for Primary Refractory Diffuse Large B Cell Lymphoma",
"Official_title" : "CD19-targeted CAR T Cells （JWCAR029） for Primary Refractory Diffuse Large B Cell Lymphoma, Phase Ⅰ,Open-label,Single-arm,Muticenter Study",
"Conditions" : ["Diff... | #Study Description
Brief Summary
This is a phase I, open-label, single-arm, multicenter study to assess the safety and efficacy of JWCAR029 in adult primary refractory DLBCL subjects in China
Detailed Description
This is a phase I, open-label, single-arm, multicenter study conducted in adult subjects with primary r... | #Eligibility Criteria:
Inclusion Criteria:
* >= 18 years;
* Sign on the informed consent;
* Subject must have histologically confirmed diffuse large B lymphoma and primary refractory with first-line therapy;
* Subjects have accessible PET-positive lesion and have measurable CT-positive lesion according to Lugano Class... | 16 |
{
"NCT_ID" : "NCT04840875",
"Brief_Title" : "Phase I Clinical Trial of Autologous CD7-CAR T Cell Therapy for High-risk Acute T-cell Leukemia/lymphoma",
"Official_title" : "Phase I Clinical Trial of Autologous CD7-CAR T Cells in the Treatment of High-risk Acute T-cell Leukemia / Lymphoma",
"Conditions" : ["T Cell Lymp... | #Study Description
Brief Summary
This is a phase 1 clinical trial of autologous CD7-CAR T cells in the treatment of high-risk acute T-cell leukemia / lymphoma. Twenty subjects will be enrolled. Subjects will be pretreated with chemotherapy prior to infusion of CAR T cells: about 3 days before cells transfusion, the p... | #Eligibility Criteria:
Inclusion Criteria:
In order to be eligible to participate in this study, an individual must meet all of the following criteria:
* Diagnosed as a high-risk acute T-cell leukemia / lymphoma patient with complete remission within 3 months and persistent positive of minimal residual disease, expre... | 76 |
{
"NCT_ID" : "NCT03338972",
"Brief_Title" : "Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma",
"Official_title" : "A Phase I Study of Adoptive Immunotherapy for Advanced B-Cell Maturation Antigen (BCMA)+ Multiple Myeloma With Autologous CD4+ and CD8+ ... | #Study Description
Brief Summary
This phase I trial studies the side effects and best dose of BCMA CAR-T cells in treating patients with BCMA positive multiple myeloma that has come back or does not respond to treatment. T cells are a type of white blood cell and a major component of the immune system. T-cells that h... | #Eligibility Criteria:
Inclusion Criteria:
* Have the capacity to give informed consent
* Eastern Cooperative Oncology Group (ECOG) performance status score =< 2.
* Have measurable disease by International Myeloma Working Group (IMWG) criteria based on one or more of the following findings:
* Serum M-protein >= 1 g... | 34 |
{
"NCT_ID" : "NCT03744676",
"Brief_Title" : "A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)",
"Official_title" : "A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory... | #Study Description
Brief Summary
This is an open-label, multicenter, Phase 2 study to determine the safety, PK, and efficacy of lisocabtagene maraleucel (JCAR017) in subjects who have relapsed from, or are refractory to, two lines of immunochemotherapy for aggressive B-cell non-Hodgkin lymphoma (NHL) in the outpatien... | #Eligibility Criteria:
Inclusion Criteria:
* Age >= 18 years at the time of consent
* Relapsed or refractory B-cell NHL of the following histologies: diffuse large B cell lymphoma (DLBCL) not otherwise specified; includes biopsy-confirmed transformed DLBCL from indolent histologies, high-grade B-cell lymphoma with MYC... | 7 |
{
"NCT_ID" : "NCT01837602",
"Brief_Title" : "cMet CAR RNA T Cells Targeting Breast Cancer",
"Official_title" : "Clinical Trial of Autologous cMet Redirected T Cells Administered Intratumorally in Patients With Breast Cancer",
"Conditions" : ["Metastatic Breast Cancer", "Triple Negative Breast Cancer"],
"Intervention... | #Study Description
Brief Summary
An open-label, clinical trial of autologous cMet redirected T cells administered intratumorally (IT) in patients with breast cancer. Fifteen evaluable patients will be enrolled in stepwise fashion. Step 1 will enroll patients with metastatic breast cancer refractory to at least 1 stan... | #Eligibility Criteria:
Inclusion Criteria:
* Step 1 subjects only: metastatic breast cancer patients with an accessible tumor (cutaneous, subcutaneous, or superficial) and/or palpable adenopathy/mass. The targeted tumor is accessible (i.e. is not near a great vessel or the spinal cord) and can be surgically excised or... | 53 |
{
"NCT_ID" : "NCT01475058",
"Brief_Title" : "CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant",
"Official_title" : "A Phase I/II Study of Cellular Immunotherapy With Donor Central Memory-derived Virus-specific CD8+ T-cells Engineered to Target CD19 for CD19+ Malignancies After Allogeneic Hematopoie... | #Study Description
Brief Summary
This phase I/II trial studies the safety and toxicity of post-transplant treatment with donor T cells engineered to express a chimeric antigen receptor (CAR) targeting CD19 in patients who have had a matched related allogeneic hematopoietic stem cell transplant for a CD19+ B cell mali... | #Eligibility Criteria:
Inclusion Criteria:
* Patients with CD19+ B cell malignancy who have persistent, relapsed or progressive disease after hematopoietic stem cell transplant from an human leukocyte antigen (HLA)-matched related donor OR patients with CD19+ B cell malignancy who are planned for or have had a hematop... | 27 |
{
"NCT_ID" : "NCT03173417",
"Brief_Title" : "Safety and Efficacy Evaluation of IM19 CAR-T Cells (IM19CAR-T)",
"Official_title" : "Safety and Efficacy Evaluation of IM19 CAR-T Cells On CD19+ Refractory or Relapsed B-ALL Patients",
"Conditions" : ["Leukemia"],
"Interventions" : ["Drug: fludarabine and cyclophosphamide... | #Study Description
Brief Summary
Assessment of the Safety and Feasibility of Administering T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor to Patients With CD19+ B-cell leukemia.
Detailed Description
Assessment of the Safety and Feasibility of Administering T Cells Expressing an Anti-CD19 Chimeric Antigen... | #Eligibility Criteria:
Inclusion Criteria:
* Patients with CD19+ Refractory or Relapsed B-ALL（At least 2 prior combination chemotherapy regimens）
* To be aged 3 <= age <= 75
* Blast in blood <= 30%
* ECOG score <=2
* Women of childbearing potential must have a urine pregnancy test taken and proven negative prior to th... | 19 |
{
"NCT_ID" : "NCT01897415",
"Brief_Title" : "Autologous Redirected RNA Meso CAR T Cells for Pancreatic Cancer",
"Official_title" : "Phase I Clinical Trial of Autologous Mesothelin Re-directed T Cells in Patients With Chemotherapy Refractory Metastatic Pancreatic Cancer",
"Conditions" : ["Subjects With Metastatic Panc... | #Study Description
Brief Summary
This is a Phase I safety and feasibility study. Subjects will be enrolled serially. For subject safety, the preceding subject must have completed one cycle of therapy (28 days) before the next subject can be treated. Subjects will be treated with i.v. administration of 1 to 3e8 per me... | #Eligibility Criteria:
Inclusion Criteria:
* Histologically confirmed metastatic pancreatic adenocarcinoma.
* Patients greater than or equal to 18 years.
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
* Life expectancy greater than 3 months.
* Evidence of metastatic disease and failure of at... | 77 |
{
"NCT_ID" : "NCT04650724",
"Brief_Title" : "Clinical Study of T Cell Infusion Targeting BCMA Chimeric Antigen Receptor",
"Official_title" : "Single Arm, Single Center, Open Label Clinical Trial of BCMA Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With BCMA Positive Recurrent or Refractory Multiple... | #Study Description
Brief Summary
Chimeric antigen receptor T cells (car-t) is one of the most effective therapies for malignant tumors (especially hematological tumors). Like other immunotherapies, the basic principle is to use the patient's own immune cells to clear cancer cells. Chimeric antigen receptor (car) is t... | #Eligibility Criteria:
Inclusion Criteria:
* 1. Subjects who voluntarily participated in the study and signed written informed consent;
2. The age of signing informed consent is 14 <= age <= 65 years;
3. Patients with multiple myeloma were diagnosed according to the IMWG diagnostic criteria;
4. The expression... | 25 |
{
"NCT_ID" : "NCT05907603",
"Brief_Title" : "Research Development（RD）13-02 Chimeric Antigen Receptor(CAR) -T Cell Injection for Patients With r/r Cluster Of Differentiation 7（CD7）+ T-Acute Lymphoblastic Leukemia(ALL)/T-Lymphoblastic Lymphoma(LBL) /Acute Myelogenous Leukemia(AML)",
"Official_title" : "Clinical Study on... | #Study Description
Brief Summary
This is a single-arm, open-label, single-center, phase I study. The primary objective is to evaluate the safety of CD7 CAR-T therapy for patients with CD7-positive relapsed or refractory T-ALL/LBL/AML, and to evaluate the pharmacokinetics of CD7 CAR-T in patients.
#Intervention
- DR... | #Eligibility Criteria:
Inclusion Criteria:
* Age 3 <= age <= 70
* Diagnosis of r/r T-ALL/LBL/AML.
* CD7 positive expression
* Bone marrow lymphoblasts >=5% by morphologic evaluation at screening
* Creatinine clearance (as estimated by Cockcroft Gault) >= 60 mL/min, Serum alanine aminotransferase(ALT)/aspartate aminotr... | 69 |
{
"NCT_ID" : "NCT06392763",
"Brief_Title" : "Care Pathway and Associated Costs of Patients Treated With CAR T-cells Based on SNDS Data",
"Official_title" : "Care Pathway and Associated Costs of Patients Treated With CAR T-cells Based on SNDS Data",
"Conditions" : ["Diffuse Large B-cell Lymphoma", "Acute Lymphoblastic... | #Study Description
Brief Summary
This retrospective cohort study, based on the French medico-administrative database (SNDS), evaluated the care pathway, the effectiveness of management and the costs associated with patients treated with chimeric antigen receptor (CAR) T cells (CART-cells) (KYMRIAH or YESCARTA): paedi... | #Eligibility Criteria:
Inclusion criteria:
DLBCL population:
* Patients with hospitalisation for CAR T-cell administration from 2017 to 2020 AND
* Diagnosed with DLBCL (International Classification of Diseases [ICD-10 C833]) when receiving CAR-T AND
* Being 18 years or older.
ALL population:
* Patients with hospita... | 13 |
{
"NCT_ID" : "NCT04316624",
"Brief_Title" : "A Study of C-CAR066 in Subjects With r/r Diffuse Large B Cell Lymphoma Who Received CD19 CAR-T Therapy",
"Official_title" : "A Study Evaluating Safety and Efficacy of CBM.CD20 CAR-T(C-CAR066) in Subjects With r/r Diffuse Large B Cell Lymphoma Who Received CD19 CAR-T Therapy... | #Study Description
Brief Summary
This is a single-center, non-randomized and dose-escalation study to evaluate the safety and efficacy of C-CAR066 in treatment of r/r DLBCL who received CD19 CAR-T therapy.
Detailed Description
This study plans to enroll 10 patients to assess the safety and efficacy of C-CAR066. Sub... | #Eligibility Criteria:
Inclusion Criteria:
* The patient volunteered to participate in the study, and signed the Informed Consent
* Age 18 <= age <= 75 years, male or female
* Patients diagnosed with diffuse large B-cell lymphoma (DLBCL, De novo or transformed) histologically according to the 2016 WHO Classification, ... | 24 |
{
"NCT_ID" : "NCT05812326",
"Brief_Title" : "PD-1 Knockout Anti-MUC1 CAR-T Cells in the Treatment of Advanced Breast Cancer",
"Official_title" : "Exploratory Clinical Study of PD-1 Knockout Targeting MUC1 CAR-T Cells (AJMUC1) in the Treatment of MUC1-positive Advanced Breast Cancer",
"Conditions" : ["Advanced Breast ... | #Study Description
Brief Summary
This exploratory clinical study aims to assess the safety and preliminary efficacy of an immunotherapy using PD-1 knockout anti-MUC1 CAR-T cells in the treatment of advanced MUC1-positive breast cancer
Detailed Description
This is a single-center, open-label, dose-escalation explora... | #Eligibility Criteria:
Inclusion Criteria:
* Patient age: 18 <= age <= 70 years (including the boundary value);
* Pathologically diagnosed with recurrent/metastatic breast cancer (except for intracranial metastasis), who have received at least one standard treatment regimen in the past, the disease is in a stable or p... | 3 |
{
"NCT_ID" : "NCT04788472",
"Brief_Title" : "Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph+ B-ALL",
"Official_title" : "Clinical Trial for the Efficacy and Safety of Sequential CD19 and CD22 CAR-T Therapy for Adult Patients with Newly Diagnosed Ph Chromosome Positive B-cell Acute Lymphoblastic Leukemia... | #Study Description
Brief Summary
Clinical Trial for the Efficacy and Safety of Sequential CD19 and CD22 CAR-T Therapy for Adult Patients With Newly Diagnosed Ph Chromosome Positive B-cell Acute Lymphoblastic Leukemia
Detailed Description
This study was designed as a prospective, open-label, single-center study. It ... | #Eligibility Criteria:
Inclusion Criteria:
* Age >= 18 years;
* Subjects with a diagnosis of B-cell acute lymphoblastic leukemia according to the 2016 edition of the WHO classification criteria for acute leukemia;
* Subjects whose chromosomal and fusion gene analysis showed positivity for the Ph chromosome, BCR/ABL1 f... | 17 |
{
"NCT_ID" : "NCT04888468",
"Brief_Title" : "Phase I Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents",
"Official_title" : "A Phase I Clinical Study of Anti-CD19 CAR-T Therapy (pCAR-19B) in the Treatment of CD19-positive Relapsed/Refractory B-ALL",
"Conditions"... | #Study Description
Brief Summary
This is a phase I clinical study to evaluate the safety and tolerability of pCAR-19B in patients with relapsed or refractory B-ALL, and to obtain the maximum tolerated dose of pCAR-19B and phase II Recommended dose.
Detailed Description
This is a single-center, single-arm, open-labe... | #Eligibility Criteria:
Inclusion Criteria:
* Diagnosed with B-ALL，and meet one of the following conditions:
1. First-line or multiple-line salvage chemotherapy did not achieve complete remission；
2. Early relapse after complete remission (<12 months), or late relapse after complete remission (>=12 months) and c... | 38 |
{
"NCT_ID" : "NCT02631044",
"Brief_Title" : "Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)",
"Official_title" : "A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R/R)... | #Study Description
Brief Summary
This open-label Phase 1 study will evaluate the safety, PK, and antitumor activity of modified T cells (JCAR017) administered to adult patients with relapsed or refractory B-cell NHL. The dose and schedule of JCAR017 will be evaluated and modified, as needed, for safety and antitumor ... | #Eligibility Criteria:
Inclusion Criteria:
* Age >=18 years
* Relapsed or refractory B-cell NHL, including
1. DLBCL cohort (no longer enrolling): DLBCL, not otherwise specified (NOS; includes transformed DLBCL from indolent histology [tDLBCL]), high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangement... | 8 |
{
"NCT_ID" : "NCT02975687",
"Brief_Title" : "CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic Leukemia",
"Official_title" : "CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic Leukemia",
"Conditions" : ["Acute Lymphoblastic Leukemia, Adult B-Cell", "... | #Study Description
Brief Summary
In this single-center, open-label, no control, prospective clinical trial, a total of 20 resistant or refractory CD19+ B cell acute lymphoblastic leukemia (ALL) patients will be enrolled. CD19 CAR T cells will be administered by i.v. injection as a using a 'split dose' (total dose of ... | #Eligibility Criteria:
Inclusion Criteria:
* Patients aged 18 <= age <= 70 with relapsed or refractory CD19 positive ALL(ie, >=20% blasts CD19-positive) due to receive either salvage 1 or salvage 2 therapy. Ph+ ALL patients must have failed treatment with at least 1 second generation tyrosine kinase inhibitor.
* Bone ... | 85 |
{
"NCT_ID" : "NCT02658929",
"Brief_Title" : "Study of bb2121 in Multiple Myeloma",
"Official_title" : "CRB-401 A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma",
"Conditions" : ["Multiple Myeloma"],
"Interventions" : ["Biological: bb2121"],
"Location_Countries" : ["United States"],
"Study_Design" : {
... | #Study Description
Brief Summary
Study CRB-401 is a 2-part, non-randomized, open label, multi-site Phase 1 study of bb2121 in adults with relapsed/refractory multiple myeloma (MM).
Detailed Description
This is a 2-part, non-randomized, open label, multi-site Phase 1 study. the study design consists of 2 parts: Part... | #Eligibility Criteria:
Inclusion Criteria:
* 18 years at the time of signing informed consent
* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
* Subjects must have measurable disease including at least one of the criteria below:
Serum M-protein greater or equal to 0.5 g/dL Urine M-protein greater... | 6 |
End of preview. Expand in Data Studio
README.md exists but content is empty.
- Downloads last month
- 3